

# Central Venous Thrombosis of the Brain After SARS-CoV-2 Infection and mRNA Vaccination

Neurologic Disaster is Even Worse After Injection

By [Dr. Peter McCullough](#)

Theme: [Science and Medicine](#)

Global Research, March 20, 2023

[Courageous Discourse](#) 18 March 2023

All Global Research articles can be read in 51 languages by activating the Translate Website button below the author's name (desktop version)

To receive Global Research's Daily Newsletter (selected articles), [click here](#).

Follow us on [Instagram](#) and [Twitter](#) and subscribe to our [Telegram Channel](#). Feel free to repost and share widely Global Research articles.

\*\*\*

*Proponents of COVID-19 mass vaccination acknowledge that similar disastrous outcomes occur with both SARS-CoV-2 infection and the COVID-19 vaccines (myocarditis, blood clots, neurological problems). They position a tradeoff and suggest you should risk it with the vaccine in hopes its lower than that of the infection. Since 94% of Americans have had the COVID-19, its water under the bridge for the infection. Early therapy reduces the invasive systemic manifestations of the illness and markedly reduces hospitalization and death including from complications. With vaccination its a different story, the full force of engineered Spike protein is felt in the body with each shot and per case, the severity of the side effect is far worse than that with COVID-19.*

Tu, et al illustrated this principle while analyzing central venous thrombosis which is a blood clot in the major vein of the brain which is a medical emergency requiring, hospitalization, intravenous or subcutaneous blood thinners, serial imaging, observation and in some cases surgery. Tu attempted to divide cases by large denominators to minimize risk; that is invalid in safety research since not all cases can be found particularly fatal ones without an autopsy. The important findings from Tu are in the tables. Central venous thrombosis after vaccination was a catastrophe with more cases, greater need for therapy, more brain surgery, and higher degrees of neurologic impairment at discharge for those who took the mRNA vaccine.



Original Investigation | Neurology

# Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore

Tian Ming Tu, MRCP; Shen Jia Yi, MRCP; Jasmine Shimin Koh, MRCP; Seyed Ehsan Saffari, PhD; Rebecca Hui Min Hoe, MRCP; Geraldine Jiangyan Chen, BSc; Hui Jin Chiew, MRCP; Carol Huilian Tham, MRCP; Christopher Ying Hao Seet, MRCP; Ming Hui Yong, MRCP; Kok Pin Yong, MRCP; Andrew Che-Fai Hui, MRCP; Bingwen Eugene Fan, MRCP; Benjamin Yong-Qiang Tan, MRCP; Amy May Lin Quek, MRCP; Raymond Chee Seong Seet, MRCP; Leonard Leong Litt Yeo, MRCP, PhD; Kevin Tan, MRCP; Umapathi N. Thirugnanam, MRCP

Table 2. Description of Patients With Cerebral Venous Thrombosis After SARS-CoV-2 Infection

Sex/age	Comorbidities	Respiratory symptoms	Positive COVID-19 tests	Neurological symptoms	Days from COVID-19 symptoms	Location of CVT	Platelet count, per 10 <sup>9</sup> /L (range 150-450)	D-dimer (range <0.5 µg/mL)	Normal thrombotic tests	Abnormal thrombotic tests	Treatment	mRS on discharge
M/21-40 y	None	None	Serology only	Seizures	NA	SSS, left transverse sinus, left sigmoid sinus, left IJV	265	4.38	Protein C, Protein S, anti-thrombin III, ACL, B2GP1, Factor V Leiden, G20210A	None	Warfarin	1
M/31-40 y	None	None	PCR	Headache, vomiting	NA	Right posterior condylar vein, right sigmoid sinus, right proximal IJV	305	4.3	ACL	None	None (had fracture of temporal bone)	0
M/31-40 y	None	Cough, pleuritic chest pain, fever	PCR	Headache	3	Left transverse and sigmoid sinuses	187	<0.19	ACL	None	Dabigatran	0
M/21-30 y	None	None	Serology only	Headache	NA	SSS, transverse sinus, torcula, sigmoid sinuses	214	Not done	ACL, LAC, B2GP1	None	LMWH	1
M/31-40 y	None	None	PCR	Seizure	NA	Left transverse and sigmoid sinuses, left IJV	255	4.56	Protein C, antithrombin III, ACL, B2GP1	Protein S 53% (low) homocysteine elevated, LAC present	Surgical decompression, heparin or warfarin	6
M/21-30 y	Smoker	None	Serology only	Headache	NA	SSS, right transverse sinus, right sigmoid sinus, right IJV, bilateral cortical veins	338	<0.5	Protein C, Protein S, anti-thrombin III, ACL, LAC, B2GP1	None	Heparin or LMWH or warfarin	1

Abbreviations: ACL, anticardiolipin antibodies; B2GP1, B2 glycoprotein I; CVT, cerebral venous thrombosis; IJV, internal jugular vein; G20210A, guanine substitution with adenine at position 20210 at the prothrombin gene; LAC, lupus anticoagulant; LMWH, low molecular weight heparin; M, male; mRS, modified Rankin scale; NA, not applicable; PCR, polymerase chain reaction; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; SSS, superior sagittal sinus.

SI conversion factors: To convert platelet counts to  $\times 10^9/\mu\text{L}$ , multiply by 1.0; to convert d-dimer to nmol/L, multiply by 5.476.

Table 3. Description of Cerebral Venous Thrombosis Following Messenger RNA SARS-CoV-2 Vaccination

Vaccine received	Sex/age, years	Co-morbidities	Presenting symptoms	Days from 1st dose of vaccine	Days from 2nd dose of vaccine	Location of CVT	Platelet count, per 10 <sup>9</sup> /L (range 150-450)	Normal thrombotic tests	Abnormal thrombotic tests	COVID-19 test	Treatment	mRS on discharge
BNT162b2	F/51-70 y	Hypertension	Headache	30	9	Right transverse, sigmoid, IJV	383	HPLA, Protein C, Protein S, anti-thrombin III, ACL, LAC, B2GP1	None	PCR negative	Surgical decompression, heparin or warfarin	5
BNT162b2	M/71-80 y	Hypertension, hyperlipidemia, diabetes	Headache	28	7	Right transverse and sigmoid sinuses	292	LAC present, ACL, B2GP1, Protein C present	None	PCR negative	Heparin or warfarin	3
BNT162b2	F/51-60 y	Hypertension, hyperlipidemia, diabetes, TIA, family history of unprovoked PE	Right sided weakness and sensory loss, Seizure	29	8	SSS, right transverse sinus, right sigmoid sinus, right IJV, bilateral cortical veins	250	Protein S, ACL, LAC, B2GP1	Antithrombin III = 55% (normal range: 80%-120%)	Not performed	LMWH or warfarin	2
BNT162b2	M/51-60 y	Hyperlipidemia	Headache, left sided weakness and vomiting	22	1	Right transverse, sigmoid sinus, IJV	300	Anti-PF4 antibody; Protein C, Protein S, anti-thrombin III, ACL, LAC, B2GP1	None	PCR and serology negative	LMWH or warfarin	2
BNT162b2	M/61-70 y	Hypertension, hyperlipidemia, diabetes	Seizures and left upper limb weakness	33	11	SSS, right transverse sinus, bilateral sigmoid sinuses	333	Protein C, Protein S, anti-thrombin III, ACL, LAC	None	PCR negative	LMWH warfarin	0
BNT162b2	M/51-60 y	DVT, scar epilepsy, encephalitis, hyperlipidemia	Headache, right sided weakness and seizure	19	NA	SSS, cortical veins	212	HPLA, Protein C, Protein S, ACL, B2GP1	Anti-PF4 antibody positive, Anti-thrombin III = 73% (normal range: 80%-130%)	PCR negative	Heparin or LMWH or dabigatran	3
mRNA-1273	M/41-50 y	Smoker	Right sided weakness and seizure	39	11	SSS, left transverse and sigmoid sinuses	224	Protein S, ACL, LAC, B2GP1 normal	Anti-thrombin III = 79% (normal range: 93%-125%), Protein C = 66% (normal range: 83%-144%) D-dimer = 1.57 (normal range: <0.5 µg/mL)	PCR and serology negative	SSS thrombectomy Heparin or LMWH or warfarin	2
mRNA-1273	M/61-70 y	Hypertension, hyperlipidemia, ischemic stroke	Right sided weakness	29	1	Right frontal superior cerebral vein	244	LAC present, Protein C, Protein S, anti-thrombin III, ACL, B2GP1	None	PCR negative	LMWH	4
mRNA-1273	M/51-60 y	None	Headache, vomiting, diplopia	23	NA	SSS, right transverse and sigmoid sinus	251	HPLA, Protein C, Protein S, anti-thrombin III, ACL, LAC	None	PCR negative	LMWH then warfarin	0

Abbreviations: ACL, anticardiolipin antibodies; B2GP1, B2 glycoprotein I; CVT, cerebral venous thrombosis; DVT, deep vein thrombosis; HPLA, heparin-induced platelet activation; ICH, intracranial hemorrhage; IJV, internal jugular vein; LAC, lupus anticoagulant; LMWH, low molecular weight heparin; mRS, modified Rankin scale; PCR, polymerase chain reaction; PF4, platelet factor 4 reactive antibodies; PE, pulmonary embolism; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; SSS, superior sagittal sinus; TIA, transient ischemic attack.

SI conversion factor: To convert platelet counts to  $\times 10^9/\mu\text{L}$ , multiply by 1.0.

Tu TM, Yi SJ, Koh JS, Saffari SE, Hoe RHM, Chen GJ, Chiew HJ, Tham CH, Seet CYH, Yong MH, Yong KP, Hui AC, Fan BE, Tan BY, Quek AML, Seet RCS, Yeo LLL, Tan K, Thirugnanam UN. Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore. JAMA Netw Open. 2022 Mar 1;5(3):e222940. doi: 10.1001/jamanetworkopen.2022.2940. PMID: 35297971; PMCID: PMC8931554.

Under no circumstances could someone accept a blood clot in the brain with the vaccine in the hopes of not getting COVID-19. That tradeoff is untenable and yet another reason why vaccine promoters have lost trust from a discerning public.

If you find “Courageous Discourse” enjoyable and useful to your endeavors, please subscribe as a paying or founder member to support our efforts in helping you engage in these discussions with family, friends, and your extended circles.

\*

Note to readers: Please click the share buttons above. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.

Source

[Tu TM, Yi SJ, Koh JS, Saffari SE, Hoe RHM, Chen GJ, Chiew HJ, Tham CH, Seet CYH, Yong MH, Yong KP, Hui AC, Fan BE, Tan BY, Quek AML, Seet RCS, Yeo LLL, Tan K, Thirugnanam UN. Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore. JAMA Netw Open. 2022 Mar 1;5\(3\):e222940. doi: 10.1001/jamanetworkopen.2022.2940. PMID: 35297971; PMCID: PMC8931554.](#)

*Featured image is from Children's Health Defense*

---

# The Worldwide Corona Crisis, Global Coup d'Etat Against Humanity

by Michel Chossudovsky

Michel Chossudovsky reviews in detail how this insidious project “destroys people’s lives”. He provides a comprehensive analysis of everything you need to know about the “pandemic” — from the medical dimensions to the economic and social repercussions, political underpinnings, and mental and psychological impacts.

*“My objective as an author is to inform people worldwide and refute the official narrative which has been used as a justification to destabilize the economic and social fabric of entire countries, followed by the imposition of the “deadly” COVID-19 “vaccine”. This crisis affects humanity in its entirety: almost 8 billion people. We stand in solidarity with our fellow human beings and our children worldwide. Truth is a powerful instrument.”*

[Conservative Risk Benefit Analyses Decide Against COVID-19 Vaccination](#)

ISBN: 978-0-9879389-3-0, Year: 2022, PDF Ebook, Pages: 164, 15 Chapters

Price: \$11.50 Get yours for FREE! [Click here to download.](#)



support the eBook project by making a donation through Global Research's ["Global Research Worldwide Corona Crisis" Campaign Page.](#)

The original source of this article is [Courageous Discourse](#)  
Copyright © [Dr. Peter McCullough](#), [Courageous Discourse](#), 2023

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Dr. Peter McCullough](#)

**Disclaimer:** The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will

not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [publications@globalresearch.ca](mailto:publications@globalresearch.ca)

[www.globalresearch.ca](http://www.globalresearch.ca) contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [publications@globalresearch.ca](mailto:publications@globalresearch.ca)